Our research analysts are industry specialists with extensive knowledge and insight. Their unique industry perspectives are featured in this monthly series.

Organized by sector teams, analysts develop their own models with criteria relevant to their industries and sectors versus applying one common set of criteria to discern intrinsic value. In addition, most of our research is generated internally, insulating us from much of Wall Street’s white noise.

Select A Year:
When is a “Turnaround” not really a “Turnaround”? »
By Austin Hawley, CFA »
December 17, 2014
“In our view, Willis is a very good company; one which can weather the short-term headwinds it faces and significantly improve its results over the next few years.”
Minimizing Bond Risks through Diligent Credit Analysis »
By John McClain, CFA »
November 19, 2014
“We like to invest in the bonds of companies that have hard assets with strong market values.”
Unlocking Alere’s Potential »
By Igor Golalic, CFA »
October 14, 2014
“Alere's core business exhibits characteristics that we want to see in companies in which we invest.”
Panic in Bermuda: When Your Business Turns into an “Interesting New Asset Class” »
By Krishna Mohanraj, CFA »
September 17, 2014
“With too much capital chasing too few opportunities, the reinsurance industry is facing an existential threat that seems more permanent than cyclical.”
Hospitals: No Longer in the ICU »
By Kyle Schneider, CFA »
August 20, 2014
“We believe LifePoint's strong free cash flow, flexible balance sheet, and conservative culture create adequate downside protection.”
Mind the Gap »
July 16, 2014
“On the surface, Gap quantitatively appears appealing but, in our opinion, less so on a qualitative basis.”
United Technologies: Uniquely Positioned to Capitalize on the Future »
June 18, 2014
“UTX management also has a solid historical track record of converting revenues into profits and free cash flow.”
Everyday Brands in the Right Hands »
By Aaron Monroe, CFA »
May 21, 2014
“The combination of an ownership mentality, long-term perspective, and disciplined capital allocation  – along with Jarden’s portfolio of strong brands – should continue to reward investors.”
Building Shareholder Value through M&A: Valeant Pharmaceuticals »
By Brian Fontanella, CFA »
April 10, 2014
“Valeant is run by executives who put shareholders first and view capital allocation as their top priority.”
Exploration & Production: An Evolving Business Model »
By Suken Patel, CFA »
March 19, 2014
“The structural changes taking place in the energy sector are creating unique long-term opportunities for some exceptionally well-positioned domestic companies.”
1 2 3 4 5 6
back to top